Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Baseline characteristics of women in the Prospective Family Study Cohort by regular aspirin use

From: Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study

  Prospective cohorta Combined cohortb
Non-regular user Regular user Non-regular User N = 6636 Regular user
N = 4616 N = 990 N = 1597
Baseline characteristic Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Age, years 41.7 (12.7) 53.1 (11.7) 44.0 (12.9) 54.2 (11.5)
Race and ethnicity, No. (%)
 Non-Hispanic white 4269 (92.5) 888 (89.7) 5860 (88.3) 1366 (85.5)
 Other 274 (5.9) 94 (9.5) 694 (10.5) 223 (14.0)
 Missing 73 (1.6) 8 (0.8) 82 (1.2) 8 (0.5)
Cigarette smoking, No. (%)
 Never 2688 (58.2) 575 (58.1) 3862 (58.2) 896 (56.1)
 Former 1088 (23.6) 267 (27.0) 1705 (25.7) 492 (30.8)
 Current 469 (10.2) 91 (9.2) 663 (10.0) 140 (8.8)
 Missing 371 (8.0) 57 (5.8) 406 (6.1) 69 (4.3)
Alcohol consumption, No. (%)
 Never 1852 (40.1) 532 (53.7) 2943 (44.4) 841 (52.7)
 Former 755 (16.4) 129 (13.0) 1062 (16.0) 220 (13.8)
 Current 1924 (41.7) 318 (32.1) 2514 (37.9) 513 (32.1)
 Missing 85 (1.8) 11 (1.1) 117 (1.8) 23 (1.4)
Hormone therapy use, No. (%)
 Never 3717 (80.5) 542 (54.8) 5255 (79.2) 895 (56.0)
 Former 409 (8.9) 191 (19.3) 758 (11.4) 361 (22.6)
 Current 430 (9.3) 230 (23.2) 522 (7.9) 290 (18.2)
 Missing 60 (1.3) 27 (2.7) 101 (1.5) 51 (3.2)
Hormonal birth control use, No. (%)
 Never 635 (13.8) 253 (25.6) 1224 (18.4) 480 (30.1)
 Former 3043 (65.9) 659 (66.6) 4373 (65.9) 1015 (63.6)
 Current 900 (19.5) 59 (6.0) 973 (14.7) 69 (4.3)
 Missing 38 (0.8) 19 (1.9) 66 (1.0) 33 (2.1)
COX-2 inhibitors, No. (%)
 Non-regular user 4227 (91.6) 814 (82.2) 6140 (92.5) 1366 (85.5)
 Regular user 358 (7.8) 161 (16.3) 428 (6.5) 199 (12.5)
 Missing 31 (0.7) 15 (1.5) 68 (1.0) 32 (2.0)
Ibuprofen and other NSAIDsc, No. (%)
 Non-regular user 3911 (84.7) 714 (72.1) 5512 (83.1) 1139 (71.3)
 Regular user 682 (14.8) 258 (26.1) 1063 (16.0) 426 (26.7)
 Missing 23 (0.5) 18 (1.8) 61 (0.9) 32 (2.0)
Acetaminophen, No. (%)
 Non-regular user 3859 (83.6) 740 (74.8) 5597 (84.3) 1214 (76.0)
 Regular user 737 (16.0) 238 (24.0) 985 (14.8) 361 (22.6)
 Missing 20 (0.4) 12 (1.2) 54 (0.8) 22 (1.4)
BOADICEA 1-year risk score, % 0.51 (0.71) 0.68 (0.85) 0.50 (0.72) 0.64 (0.83)
Mutation carrier status, No. (%)
 Non-carrierd 4070 (88.2) 915 (92.4) 5739 (86.5) 1440 (90.2)
BRCA1 mutation carrier 292 (6.3) 37 (3.7) 500 (7.5) 84 (5.3)
BRCA2 mutation carrier 254 (5.5) 38 (3.8) 397 (6.0) 73 (4.6)
  1. aIncludes women with no personal history of breast cancer when regular medication use was asked by questionnaire (N = 5606)
  2. bIncludes retrospective breast cancer cases (diagnosed prior to baseline and/or follow-up questionnaire) and prospective breast cancer cases (diagnosed after follow-up questionnaire) (N = 8233)
  3. cNon-steroidal anti-inflammatory drugs
  4. dIncludes true negatives and women who did not undergo genetic testing for BRCA1 and BRCA2